---
title: "Kepler Capital  Sticks to Their Buy Rating for Royal UNIBREW A/S (0R6Z)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281593763.md"
description: "Kepler Capital has maintained a Buy rating for Royal UNIBREW A/S (0R6Z) with a price target of DKK710.00, while the shares closed at DKK535.00. Analyst Richard Withagen is ranked #11170 out of 12068 analysts. The overall analyst consensus for Royal UNIBREW A/S is a Strong Buy, with an average price target of DKK670.25."
datetime: "2026-04-03T01:56:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281593763.md)
  - [en](https://longbridge.com/en/news/281593763.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281593763.md)
---

# Kepler Capital  Sticks to Their Buy Rating for Royal UNIBREW A/S (0R6Z)

In a report released on April 1, Richard Withagen from Kepler Capital maintained a Buy rating on Royal UNIBREW A/S, with a price target of DKK710.00. The company’s shares closed last Wednesday at DKK535.00.

### End of Quarter Sale - 50% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Withagen is ranked #11170 out of 12068 analysts.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Royal UNIBREW A/S with a DKK670.25 average price target.

### Related Stocks

- [BRBL.US](https://longbridge.com/en/quote/BRBL.US.md)

## Related News & Research

- [Walmart Stock: Here’s Why Analysts Are Raising Price Targets Before Q1 Earnings.](https://longbridge.com/en/news/286950969.md)
- [Q2 EPS Forecast for Avalo Therapeutics Boosted by Analyst](https://longbridge.com/en/news/286903837.md)
- [Earnings Beat: Deepak Nitrite Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models](https://longbridge.com/en/news/286980047.md)
- [Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4](https://longbridge.com/en/news/286958909.md)
- [LifeSci Capital Sticks to Their Buy Rating for Olema Pharmaceuticals (OLMA)](https://longbridge.com/en/news/286679129.md)